Treatments Compared for Advanced Renal Cell Carcinoma
Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients
Renal Cell Carcinoma
Keytruda Approved as Adjuvant Treatment for Renal Cell Carcinoma After Surgery
The approval was based on data from the pivotal phase 3 KEYNOTE-564 trial, which included 994 adults with RCC who have undergone nephrectomy and who have intermediate-high, high risk, or M1 no evidence of disease (M1 NED) RCC with clear cell component.
Welireg Approved for Cancers Associated With Von Hippel-Lindau Disease
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
Keytruda Plus Lenvima Approved for Advanced Renal Cell Carcinoma
The approval was based on data from the pivotal phase 3 CLEAR (Study 307)/KEYNOTE-581 trial.
FDA to Review Pembrolizumab for Additional Kidney, Endometrial Cancer Indications
The sBLA submissions are supported by data from the phase 3 KEYNOTE-564 trial and the phase 2 KEYNOTE-158 trial.
Fotivda Now Available for Renal Cell Carcinoma
Fotivda is an oral vascular endothelial growth factor tyrosine kinase inhibitor.
Belzutifan Gets Priority Review for Von Hippel-Lindau Disease-Associated RCC
Belzutifan is a potent and selective inhibitor of HIF-2α.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Jury Penalizes Physician for Failing to Follow Up on Abnormal Urinalysis
This month’s case addresses the issues of when to act on abnormal test results.
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
